Ignite Creation Date:
2025-12-24 @ 1:37 PM
Ignite Modification Date:
2025-12-30 @ 1:11 PM
Study NCT ID:
NCT05764395
Status:
SUSPENDED
Last Update Posted:
2024-10-10
First Post:
2023-02-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-09
Start Date Type:
ACTUAL
Primary Completion Date:
2028-05-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-05-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-28
First Submit QC Date:
None
Study First Post Date:
2023-03-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-07
Last Update Post Date:
2024-10-10
Last Update Post Date Type:
ACTUAL